Your browser doesn't support javascript.
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Garcia-Beltran, Wilfredo F; Lam, Evan C; St Denis, Kerri; Nitido, Adam D; Garcia, Zeidy H; Hauser, Blake M; Feldman, Jared; Pavlovic, Maia N; Gregory, David J; Poznansky, Mark C; Sigal, Alex; Schmidt, Aaron G; Iafrate, A John; Naranbhai, Vivek; Balazs, Alejandro B.
  • Garcia-Beltran WF; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Lam EC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • St Denis K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Nitido AD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Garcia ZH; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Pavlovic MN; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Gregory DJ; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Pedriatric Infectious Disease, Massachusetts General Hospital for Children, Boston, MA 02114, USA.
  • Poznansky MC; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Sigal A; Africa Health Research Institute, Durban 4001, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4041, South Africa; Max Planck Institute for Infection Biology, Berlin 10117, Germany.
  • Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Naranbhai V; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.
  • Balazs AB; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.
Cell ; 184(9): 2372-2383.e9, 2021 04 29.
Article in English | MEDLINE | ID: covidwho-1343151
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.CELL.2021.03.013

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.CELL.2021.03.013